country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-146088

Copy Link Print Information

HIV-1 inhibitor-31

HIV-1 inhibitor-31 (compound 4) is a potent HIV-1 inhibitor. HIV-1 inhibitor-31 can be used for researching AIDS.

For research use only. We do not sell to patients.

CAS No.: 920036-04-0
Formula: C₂₁H₁₃Cl₂N₃O₂
Molecular Weight:410.25

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (269 KB)

HIV-1 inhibitor-31 Chemical Structure

CAS No.: 920036-04-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

HIV-1 inhibitor-31 (compound 4) is a potent HIV-1 inhibitor. HIV-1 inhibitor-31 can be used for researching AIDS^[1].

IC₅₀ & Target

HIV-1^[1]

All HIV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
MT4	IC₅₀	13.8 nM Compound: 22	Antiviral activity against HIV1 with RT Y181C mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT Y181C mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	141 nM Compound: 22	Antiviral activity against HIV1 with RT K103N/Y181C mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT K103N/Y181C mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	171 nM Compound: 22	Antiviral activity against HIV1 with RT K103N/Y181C/G190A mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT K103N/Y181C/G190A mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	2.6 nM Compound: 22	Antiviral activity against HIV1 with RT L100I mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT L100I mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	20.3 nM Compound: 22	Antiviral activity against HIV1 with RT K103N/V179E mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT K103N/V179E mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	21 nM Compound: 22	Antiviral activity against HIV1 with RT K101E/G190A mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT K101E/G190A mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	21.7 nM Compound: 22	Antiviral activity against HIV1 with RT K103N/G190A mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT K103N/G190A mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	23.4 nM Compound: 22	Antiviral activity against HIV1 with RT G190S mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT G190S mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	29.3 nM Compound: 22	Antiviral activity against HIV1 with RT K103N/P225H mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT K103N/P225H mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	35.8 nM Compound: 22	Antiviral activity against HIV1 with RT Y181C/G190A mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT Y181C/G190A mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	4.7 nM Compound: 22	Antiviral activity against HIV1 in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	7.9 nM Compound: 22	Antiviral activity against HIV1 with RT K103N mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT K103N mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	9.4 nM Compound: 22	Antiviral activity against HIV1 with RT G190A mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT G190A mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]
MT4	IC₅₀	>1000 nM Compound: 22	Antiviral activity against HIV1 with RT Y188L mutation in human MT4 cells in presence of 40% normal human serum Antiviral activity against HIV1 with RT Y188L mutation in human MT4 cells in presence of 40% normal human serum	[PMID: 18396399]

Chemical Information

CAS No. 920036-04-0
Molecular Weight 410.25
Formula C₂₁H₁₃Cl₂N₃O₂
SMILES

N#CC1=CC(OC2=CC(OCC3=NNC4=C3C=CC=C4)=CC=C2Cl)=CC(Cl)=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (269 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Xiao T, et al. Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities. Eur J Med Chem. 2020;186:111864. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

HIV-1 inhibitor-31

All HIV Isoforms

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

HIV-1 inhibitor-31 Related Classifications

HY-146088 Related Classifications